Compare Amgen, Inc. (AMGN) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Global X SuperDividend ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Global X SuperDividend ETF trades at $24.6. The key difference: Amgen, Inc. pays a 2.77% dividend while Global X SuperDividend ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SDIV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $388.16 | $26.34 |
52-Week Low | $271.18 | $22.90 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SDIV trades at $24.60, up 0.94% in the past 24 hours, with a bearish technical signal driven by moving averages. The ETF offers a high dividend yield, recently paying $0.18 per share quarterly, attracting income-focused investors. Recent news highlights its appeal for diversification away from tech and its 9.29% yield, though valuation ratios like P/E and P/B are unavailable. Support and resistance cluster around $24-$25, indicating tight price consolidation.
Outlook remains mixed; the high yield and non-tech exposure provide income opportunities, but bearish technicals and reliance on global small-cap value stocks pose risks. Investors should weigh the attractive dividends against potential volatility from economic shifts and sector concentration in Financials and Energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
